Hemcheck Sweden AB has signed a subscription agreement with Tartu university hospital regarding delivery of readers and one-time disposables (v-Test) for usage at the hematology and oncology clinic. The agreement has been signed after a test period which has been ongoing since the spring with good results. The agreement implies ca 18 000 EUR depending on volume in yearly revenue for Hemcheck.

–This agreement is a good marker for the attractiveness of our solution, and it is very positive that Tartu university hospital want to implement our system to reduce the issues related to hemolyzed blood samples. The hospital has evaluated the system during a longer period of time, and we are very happy that they are satisfied. We hope this is the start of a longer and broader collaboration with Tartu, says Joen Averstad, CEO of Hemcheck.

–We have tested Hemcheck’s system both in the hospital laboratory and in some clinics, with good results, so we are very satisfied to have signed this agreement with Hemcheck. With this system we will be able to provide better care and service to our patients as well as helping our staff, says Anu Tamm, head of the laboratories at Tartu university hospital.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 076 108 8191

Email: joen.averstad@hemcheck.com

About Tartu University Hospital

Tartu university hospital was founded in the early 19th century. Today it has almost 1 000 beds and over 3 000 employees. It is the largest and most highly specialized hospital in Estonia. It’s a national reference center for healthcare and biomedicine in Estonia.

Read more at: https://www.kliinikum.ee/en/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on October 20, 2020 at 23.00